39 related articles for article (PubMed ID: 3163419)
1. Physiologic variations of serum tumor markers in gynecological malignancies during pregnancy: a systematic review.
Han SN; Lotgerink A; Gziri MM; Van Calsteren K; Hanssens M; Amant F
BMC Med; 2012 Aug; 10():86. PubMed ID: 22873292
[TBL] [Abstract][Full Text] [Related]
2. Clinical Applicability of Tissue Polypeptide Antigen and CA-125 in Gynecological Malignancies.
Schröder L; Domroese CM; Rupp ABA; Gihr KME; Niederau C; Mallmann MR; Holdenrieder S
Biomedicines; 2023 Nov; 11(11):. PubMed ID: 38001961
[TBL] [Abstract][Full Text] [Related]
3. Correction to: Serum expression of tumor marker CA242 in patients with different gynecological diseases.
Lab Med; 2023 May; ():. PubMed ID: 37133837
[No Abstract] [Full Text] [Related]
4. Serum markers CASA and CA 15-3 in ovarian cancer: all MUC1 assays are not the same.
Devine PL; McGuckin MA; Quin RJ; Ward BG
Tumour Biol; 1994; 15(6):337-44. PubMed ID: 7997805
[TBL] [Abstract][Full Text] [Related]
5. Tumour marker CA15-3: possible uses in the routine management of breast cancer.
Tomlinson IP; Whyman A; Barrett JA; Kremer JK
Eur J Cancer; 1995 Jun; 31A(6):899-902. PubMed ID: 7646918
[TBL] [Abstract][Full Text] [Related]
6. CA 15-3 as a tumor marker in gynecological malignancies.
Scambia G; Benedetti Panici P; Baiocchi G; Perrone L; Greggi S; Mancuso S
Gynecol Oncol; 1988 Jun; 30(2):265-73. PubMed ID: 3163666
[TBL] [Abstract][Full Text] [Related]
7. Multiple biomarkers are more accurate than a combination of carbohydrate antigen 125 and human epididymis protein 4 for ovarian cancer screening.
Kang KN; Koh EY; Jang JY; Kim CW
Obstet Gynecol Sci; 2022 Jul; 65(4):346-354. PubMed ID: 35443557
[TBL] [Abstract][Full Text] [Related]
8. On Demand Biosensors for Early Diagnosis of Cancer and Immune Checkpoints Blockade Therapy Monitoring from Liquid Biopsy.
Mummareddy S; Pradhan S; Narasimhan AK; Natarajan A
Biosensors (Basel); 2021 Dec; 11(12):. PubMed ID: 34940257
[TBL] [Abstract][Full Text] [Related]
9. Serum tumor markers in the management of ovarian, endometrial and cervical cancer.
Gadducci A; Cosio S; Carpi A; Nicolini A; Genazzani AR
Biomed Pharmacother; 2004 Jan; 58(1):24-38. PubMed ID: 14739059
[TBL] [Abstract][Full Text] [Related]
10. The role of tumour markers in ovarian cancer.
Gargano G; Correale M; Abbate I; Falco G; De Frenza N; Lorusso V; De Lena M; De Leonardis A
Clin Exp Obstet Gynecol; 1990; 17(1):23-9. PubMed ID: 2194706
[TBL] [Abstract][Full Text] [Related]
11. CA 15-3 serum levels in ovarian cancer.
Scambia G; Benedetti Panici P; Baiocchi G; Perrone L; Greggi S; Di Roberto P; Mancuso S
Oncology; 1988; 45(3):263-7. PubMed ID: 3163419
[TBL] [Abstract][Full Text] [Related]
12. Measurement of a monoclonal-antibody-defined antigen (90K) in the sera of patients with ovarian cancer.
Scambia G; Panici PB; Baiocchi G; Perrone L; Iacobelli S; Mancuso S
Anticancer Res; 1988; 8(4):761-4. PubMed ID: 3178164
[TBL] [Abstract][Full Text] [Related]
13. Clinical evaluation of circulating serum sialyl Tn antigen levels in patients with epithelial ovarian cancer.
Kobayashi H; Terao T; Kawashima Y
J Clin Oncol; 1991 Jun; 9(6):983-7. PubMed ID: 1851822
[TBL] [Abstract][Full Text] [Related]
14. Clinical evaluation of tumor-associated mucin-type glycoprotein CA 54/61 in ovarian cancers: comparison with CA 125.
Suzuki M; Sekiguchi I; Tamada T
Obstet Gynecol; 1990 Sep; 76(3 Pt 1):422-7. PubMed ID: 2381620
[TBL] [Abstract][Full Text] [Related]
15. Elevation of multiple serum markers in patients with stage I ovarian cancer.
Woolas RP; Xu FJ; Jacobs IJ; Yu YH; Daly L; Berchuck A; Soper JT; Clarke-Pearson DL; Oram DH; Bast RC
J Natl Cancer Inst; 1993 Nov; 85(21):1748-51. PubMed ID: 8411259
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
